Cryptococcal antigen screening for patients initiating antiretroviral therapy: Time for action

Clinical Infectious Diseases

Volumn 51, Issue 12, 2010, Pages 1463-1465

  Jarvis, Joseph N ^a,b,c   Lawn, Stephen D ^a,d   Wood, Robin ^a   Harrison, Thomas S ^a,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GF Jooste Hospital   (South Africa)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CRYPTOCOCCAL ANTIGEN; FLUCONAZOLE; FUNGUS ANTIGEN; UNCLASSIFIED DRUG;

CD4 LYMPHOCYTE COUNT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; LETTER; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; SCREENING;

ANTIGENS, FUNGAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CRYPTOCOCCOSIS; HIV INFECTIONS; HUMANS; INCIDENCE; MASS SCREENING; SOUTH AFRICA;

EID: 78649898139     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657405     Document Type: Letter

References (13)

1. + cell count ≤100 cells/μL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010; 51:448-455.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-530.
3. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010; 10:67.
4. Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa. J Infect 2010; 60:496-498.
5. Jarvis JN, Lawn SD, Vogt M, Bangani N,Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856-862.
6. Jarvis JN, Meintjes G, Wood R, Harrison TS. Testing but not treating: missed opportunities and lost lives in the South African anti-retroviral therapy programme. AIDS 2010; 24:1233-1235.
7. Lawn S, Harries A, Anglaret X, Myer L,Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
8. Haile B, Maartens G,Wood R. Economic evaluation of cryptococcal meningitis and inpatient tuberculosis treatment for HIV-infected adults in South Africa [abstract 25431]. In: Program and abstracts of the 129th Annual Meeting of the American Public Health Association (Atlanta). 2001.
9. Harling G, Orrell C, Wood R. Healthcare utilization of patients accessing an African national treatment program. BMC Health Serv Res 2007; 7:80.
10. John L, Nelson M. Primary prophylaxis for cryptococcal meningitis. HIV Med 2004; 5: 131-132.
11. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 1997; 17: 373-381.
12. Yazdanpanah Y, Goldie SJ, Paltiel AD, et al. Prevention of human immunodeficiency virus- related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis 2003; 36:86-96.
13. Freedberg KA, Scharfstein JA, Seage GR 3rd, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279:130-136.